FindTrial
Sign In

Re-evaluation of anti-TNF use in a cohort of IBD patients in a non-academic hospital.

Re-evaluation of anti-TNF use in a cohort of IBD patients in a non-academic hospital. - stop anti TNF.

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON38980
Enrollment
50
Registered
2014-04-15
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel disease

Interventions

treatment with thiopurines.

Sponsors

Martini Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 18 years or older mentally compentent diagnose of IBD signed informed consent well known history

Exclusion criteria

Exclusion criteria: pregnant women existing treatment with MTX history of fistels second indication for anti TNF, such as Bechterew serious co-morbidiy unable to understand or write Dutch serious transfusionreaction on infliximab or Humira in the past

Design outcomes

Secondary

MeasureTime frame
1. Which subgroups are present? 2. Which % and which subgroups can be succesfully changed into a optimized thiopurine treatment. (with TNF treatment) 3. Which % and which subgroup can stop the anti-TNF long term (> one year)?—

Primary

MeasureTime frame
Which % of the studypopulation is succesfully changed into optimized thiopurine treatment?—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)